Hemogenyx Pharmaceuticals
HEMO · Main Market · Health Care · mcap £51m · 735.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 30 Sep 26 | Routine | Total Voting Rights | |
| 28 Sep 26 | Results | Half-year Results
H1 2026: FDA cleared paediatric AML arm, second dose level ready, £5.6m raised, manufacturing transitioned. |
+3.2% |
| 03 Sep 26 | Exercise of Warrants and Issue of Equity
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received notices to exercise warrants over 96,825 new ordinary shares in the Company (the "Warrant Shares"). |
+6.9% | |
| 11 Aug 26 | Collaboration with Cellin Technologies
Hemogenyx signs definitive collaboration with Cellin Technologies to manufacture and commercialize HG-CT-1 CAR-T therapy in Estonia under Hospital Exemption framework. |
+1.9% | |
| 29 Jul 26 | Collaboration and Company Update
Hemogenyx signs collaboration with Lithuanian hospital on FLT3-positive AML/MDS research and point-of-care CAR-T therapy manufacturing. |
−8.5% | |
| 01 Jul 26 | Routine | Result of AGM | |
| 05 Jun 26 | Routine | Notice of AGM | |
| 29 May 26 | Routine | Grant of Options and Extension of Warrant Term | |
| 30 Apr 26 | Results | Final Results
Phase 1 trial of HG-CT-1 CAR-T therapy dosed three patients, advanced to dose escalation, opened paediatric arm. |
−0.7% |
| 28 Apr 26 | Fundraise | Institutional Fundraise
Hemogenyx raises £3m from institutional investors to accelerate HG-CT-1 Phase 1 trials and early commercialisation. |
−14.1% |
| 14 Apr 26 | Annual IND Report with FDA
Hemogenyx submitted its second annual IND report to the FDA for HG-CT-1 CAR-T therapy, with three patients treated showing CAR-T expansion and blast reduction. |
−11.4% | |
| 31 Mar 26 | Tech Transfer Completion and Clinical Trial Update
Technology transfer of HG-CT-1 manufacturing to contract manufacturer completed; FDA comparability data submitted; clinical trial recruitment expanding. |
+2.1% | |
| 27 Feb 26 | Routine | Total Voting Rights | |
| 24 Feb 26 | Holding | Holding(s) in Company | |
| 23 Feb 26 | Exercise of Warrants and Issue of Equity
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received notices to exercise warrants over 50,841 new ordinary shares in the Company (the "Warrant Shares"). |
+4.7% | |
| 10 Feb 26 | Routine | Issue of Equity - Correction | |
| 10 Feb 26 | Routine | Issue of Equity | |
| 30 Jan 26 | Routine | Total Voting Rights | |
| 12 Jan 26 | Holding | Holding(s) in Company | |
| 22 Dec 25 | Update on Admission of Shares
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, provides an update to the admission of new ordinary shares as announced on 18 December 20 |
+6.0% | |
| 18 Dec 25 | Routine | Issue of Equity | |
| 08 Dec 25 | Holding | Holding(s) in Company | |
| 28 Nov 25 | Routine | Total Voting Rights | |
| 19 Nov 25 | Routine | Publication of Prospectus | |
| 29 Oct 25 | Clinical Trial Update and Grant of Share Awards
DSMB cleared HG-CT-1 CAR-T therapy to advance to next dose level; pediatric recruitment opened. |
+4.1% | |
| 06 Oct 25 | Clearance to Initiate Pediatric Enrolment
MD Anderson IRB approves expansion of HG-CT-1 Phase I trial to include pediatric patients with relapsed or refractory AML. |
+7.9% |
Company filings. Not investment advice.